Patents by Inventor Uri Saragovi
Uri Saragovi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140004119Abstract: There are provided herein novel monoclonal antibodies that selectively bind and/or activate TrkC receptors, pharmaceutical compositions thereof and the use thereof for treating or preventing conditions which require activation of TrkC, such as amyotrophic lateral sclerosis and other neurodegenerative conditions and motor neuron diseases. The monoclonal antibodies are useful to screen for agents that share the same binding epitope on the TrkC receptor.Type: ApplicationFiled: November 30, 2010Publication date: January 2, 2014Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITYInventors: Horacio Uri Saragovi, VĂ©ronique Guillemard, Neil Cashman
-
Publication number: 20130310404Abstract: Novel p75 receptor antagonist compounds and compositions and uses thereof for the prevention and treatment of p75-associated disorders, such as neurodegenerative diseases, are described.Type: ApplicationFiled: October 13, 2011Publication date: November 21, 2013Inventors: Horacio Uri Saragovi, Hinyu Nedev
-
Patent number: 8563520Abstract: The present invention relates to methods to treat glaucoma and glaucoma-related conditions through the regulation of changes in gene expression that are mediated by high intraocular pressure or ?2 macroglobulin administration. Glaucoma, retinal ganglion cell (RGC) death and chronic ocular hypertension are treated using pharmaceutical compositions which comprise substances that inhibit the expression or activity of intraocular pressure-regulated early genes (IPREGs) or their gene products that are up-regulated by high intraocular pressure or ?2 macroglobulin administration and/or which increase the expression or activity of IPREGs or their gene products that are down-regulated by high intraocular pressure or ?2 macroglobulin administration. The invention also relates to methods of identifying an IPREG and methods to test for chronic ocular degeneration and the onset of RGC stress in an individual by measuring the expression level of IPREG proteins.Type: GrantFiled: May 22, 2008Date of Patent: October 22, 2013Assignee: McGill UniversityInventor: H. Uri Saragovi
-
Patent number: 8512702Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.Type: GrantFiled: December 14, 2011Date of Patent: August 20, 2013Assignee: Proscan Rx Pharma Inc.Inventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Nicole Bernard, Serge Moffett
-
Publication number: 20120082618Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.Type: ApplicationFiled: December 14, 2011Publication date: April 5, 2012Applicant: PROSCAN RX PHARMA INC.Inventors: CLAUDIO CUELLO, URI SARAGOVI, PIERRE DU RUISSEAU, PHIL GOLD, NICOLE BERNARD, SERGE MOFFETT
-
Patent number: 8101713Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.Type: GrantFiled: September 10, 2010Date of Patent: January 24, 2012Assignee: Proscan RX Pharma Inc.Inventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Nicole Bernard, Serge Moffett
-
Patent number: 7910693Abstract: The present invention relates to novel mimetopes of anti-PSMA antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastatis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.Type: GrantFiled: April 19, 2005Date of Patent: March 22, 2011Assignee: ProScan Rx Pharma Inc.Inventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Serge Moffett
-
Publication number: 20110064654Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.Type: ApplicationFiled: September 10, 2010Publication date: March 17, 2011Applicant: Proscan Rx Pharma Inc.Inventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Nicole Bernard, Serge Moffett
-
Patent number: 7811564Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.Type: GrantFiled: January 28, 2004Date of Patent: October 12, 2010Assignee: Proscan RX PharmaInventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Nicole Bernard, Serge Moffet
-
Publication number: 20100048461Abstract: The present invention relates to methods of treating or preventing retinal ganglion cell (RGC) death and/or glaucoma using modulators of neurotrophic receptors that comprise ?-turn peptidomimetic cyclic compounds or derivatives thereof. The neurotrophic receptor modulators can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat or prevent ocular hypertension, RGC death and/or glaucoma.Type: ApplicationFiled: December 5, 2007Publication date: February 25, 2010Inventor: H. Uri Saragovi
-
Publication number: 20090131277Abstract: The present invention relates to novel mimetopes of anti-PSMA antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastatis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.Type: ApplicationFiled: April 19, 2005Publication date: May 21, 2009Applicant: PROSCAN RX PHARMAInventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Serge Moffett
-
Publication number: 20080305103Abstract: The present invention relates to methods to treat glaucoma and glaucoma-related conditions through the regulation of changes in gene expression that are mediated by high intraocular pressure or ?2 macgroglobulin administration. Glaucoma, retinal ganglion cell (RGC) death and chronic ocular hypertension are treated using pharmaceutical compositions which comprise substances that inhibit the expression or activity of intraocular pressure-regulated early genes (IPREGs) or their gene products that are up-regulated by high intraocular pressure or ?2 macgroglobulin administration and/or which increase the expression or activity of IPREGs or their gene products that are down-regulated by high intraocular pressure or ?2 macgroglobulin administration. The invention also relates to methods of identifying an IPREG and methods to test for chronic ocular degeneration and the onset of RGC stress in an individual by measuring the expression level of IPREG proteins.Type: ApplicationFiled: May 22, 2008Publication date: December 11, 2008Inventor: H. Uri Saragovi
-
Patent number: 7423114Abstract: The invention provides ligands of ganglioside GD2, including peptide ligands such as GGITNYNSALM; YCGGITNYNSACY; YCITNYNSCY; YCGGITNYNCY; YCTNYGVHCY; YCTNYGVCY; GGIANYNTS; YCGGIANYNCY; YCGGIANYNTSCY; and, YCIANYNTCY. GD2 ligands of the invention may for example be used to treat or diagnose diseases such as cancers in which cells express GD2, including neuroblastomas.Type: GrantFiled: November 28, 2005Date of Patent: September 9, 2008Assignee: McGill UniversityInventors: Martin Gagnon, H. Uri Saragovi
-
Publication number: 20070036719Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.Type: ApplicationFiled: January 28, 2004Publication date: February 15, 2007Inventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Nicole Bernard, Serge Moffet
-
Patent number: 6881719Abstract: Proteolytically stable small molecule ?-turn peptidomimetic compounds have been identified as agonists or antagonists of neurotrophin receptors, such as TrkA. A compound of particular interest binds the immunoglobulin-like C2 region of the extracellular domain of TrkA, competes the binding of another TrkA ligand, affords selective trophic protection to TrkA-expressing cell lines and neuronal primary cultures, and induces the differentiation of primary neuronal cultures. The small ?-turn peptidomimetic compounds of the invention can activate a tyrosine kinase neurotrophin receptor that normally binds a relatively large protein ligand. Such compounds that bind the extracellular domain of Trk receptors are useful pharmacological agents to address disorders where Trk receptors play a role, by targeting populations selectively.Type: GrantFiled: January 18, 2001Date of Patent: April 19, 2005Assignees: McGill University, The Texas A&M University SystemInventors: Horacio Uri Saragovi, Kevin Burgess
-
Publication number: 20030211982Abstract: Proteolytically stable small molecule &bgr;-turn peptidomimetic compounds have been identified as agonists or antagonists of neurotrophin receptors, such as TrkA. A compound of particular interest binds the immunoglobulin-like C2 region of the extracellular domain of TrkA, competes the binding of another TrkA ligand, affords selective trophic protection to TrkA-expressing cell lines and neuronal primary cultures, and induces the differentiation of primary neuronal cultures. The small &bgr;-turn peptidomimetic compounds of the invention can activate a tyrosine kinase neurotrophin receptor that normally binds a relatively large protein ligand. Such compounds that bind the extracellular domain of Trk receptors are useful pharmacological agents to address disorders where Trk receptors play a role, by targeting populations selectively.Type: ApplicationFiled: November 18, 2002Publication date: November 13, 2003Inventors: Horacio Uri Saragovi, Kevin Burgess
-
Patent number: 6610500Abstract: The present invention relates to an agonistic anti-human TrkA mAb 5C3 which recognizes the NGF docking site. Such antibodies may be used for the treatment, diagnosis or prevention of neurological diseases, neuromas and neoplastic tumors which express TrkA receptors. Also these antibodies may be used to develop and screen for pharmaceutical agents which are agonistic or antagonistic to NGF binding to the TrkA receptors.Type: GrantFiled: June 8, 1998Date of Patent: August 26, 2003Assignee: McGill UniversityInventors: H. Uri Saragovi, Lynne LeSauteur
-
Publication number: 20030158237Abstract: Disclosed is a pharmaceutical composition for the treatment of cognitive symptoms caused by Alzheimer's disease in a mammal. This composition comprising vitamin E, quercitin, caffeic acid, nicotinic acid or derivatives and/or analog thereof, and a pharmaceutically acceptable excipient.Type: ApplicationFiled: September 4, 2002Publication date: August 21, 2003Applicant: Colba R & D Inc.Inventors: Uri Saragovi, Joseph Bassili, Khassam Elfarrah